Bjerre M, Gram LF, Kragh-Sorensen P, Kristensen CB, Pedersen OL, Moller M, Thayssen P (1981)

Dose-dependent kinetics of imipramine in elderly patients. Psychopharmacology 75(4):

354–357

Bogetti-Salazar M, Gonzalez-Gonzalez C, Juarez-Cedillo T, Sanchez-Garcia S, Rosas-Carrasco O

(2016) Severe potential drug-drug interactions in older adults with dementia and associated

factors. Clinics (Sao Paulo) 71(1):17–21

Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E (2000) Comparison of

setraline and nortrityline in the treatment of major depressive disorder in late life. Am J

Psychiatry 157(5):729–936

Bourin M, Chue P, Guillon Y (2001) Paroxetine: a review. CNS Drug Rev 7(1):25–47

Breslin JW, Yang Y, Scallan JP, Sweat RS, Adderley SP, Murfee WL (2019) Lymphatic vessel

network structure and physiology. Compr Physiol 9:207–299

Chung H, Kim A, Lim KS, Park S-I, Yu K-S, Yoon SH, Cho J-Y, Chung J-Y (2017) Pharmacoki-

netics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly

compared with younger adults. Int Clin Psychopharmacol 32(1):20–26

Cipriani A, Purgato M, Furukawa FA, Trespidi C, Imperadore G, Signoretti A, Churchill R,

Watanabe N, Barbui C (2014) Citalopram versus other anti-depressive agents for depression.

Cochrane Database Syst Rev 7:CD006534

Clemente JC, Ursell LK, Parfrey LW, Knight R (2012) The impact of the gut microbiota on human

health: an integrative view. Cell 148(6):1258–1270

Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of chronic kidney disease

and decreased kidney function in the adult US population: Third National Health and Nutrition

Examination Survey. Am J Kidney Dis 41(1):1–12

Cӑtoi AF, Corina A, Katsiki N, Vodnar DC, Andreicut AD, Stoian AP, Rizzo M, Pérez-Martinez P

(2020) Gut microbiota and aging—a focus on centenarians. BBA-Mol Basis Dis 1866(7):1–10.

https://doi.org/10.1016/j.bbadis.2020.165765

Dawling S, Crome P, Braithwaite RA, Lewis RR (1980) Nortriptyline therapy in elderly patients:

dosage prediction after single dose pharmacokinetic study. Eur J Clin Pharmacol 18(2):147–150

Demir N, Yuruyen M, Yavuzer H, Hatemi I, Doventas A, Erdincler DS, Dobrucali A (2017)

Prevalence of fecal incontinence and associated rosk factors in elderly outpatients: a cross-

sectional study. Aging Clin Exp Res 29(6):1165–1171

Diao JA, Inker LA, Levey AS, Tighiouart H, Powe NR, Manrai AK (2021) In search of a better

equation—performance and equity in estimates of kidney function. N Engl J Med 385(5):

396–399

Drozda K, Müller DJ, Bishop JR (2014) Pharmacogenomic testing for neuropsychiatric drugs:

current status of drug labeling, guidelines for using genetic information, and test options.

Pharmacotherapy 34(2):166–184

Ellis JJ, Sadosky AB, Ten Eyck LL, Mudumby P, Cappelleri JC, Ndahi L, Suehs BT, Parsons B

(2015) A retrospective, matched cohort study of potential drug-drug interaction prevalence and

opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or

duloxetine. BMC Health Serv Res 15:159. https://doi.org/10.1186/s12913-015-0829-9

English BA, Dortch M, Lereshefsky L, Jhee S (2012) Clinically significant psychotropic drug-drug

interactions in the primary care setting. Curr Psyciatry Rep 14(4):376–390

Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A (1988) Pharmacokinetic factors affecting

antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine—new

data and review. Clin Chem 34(5):863–880

Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S (2019) A review of novel antidepressants: a

guide for clinicians. Cureus 11(3):e4185. https://doi.org/10.7759/cureus.4185

Feng Y, Bollock BG, Farrell RE, Kimak MA, Reynolds CF III, Bies RR (2006) Paroxetine:

population pharmacokinetic analysis in late-life depression using sparse concentration sam-

pling. Br J Clin Pharmacol 61(5):558–569

Ferguson JM, Hill H (2006) Pharmacokinetics of fluoxetine in elderly men and women. Gerontol-

ogy 52(1):45–50

266

M. Bhaskar et al.